Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
xcellbio logo — Improving therapeutic performance for predictive clinical ou...

xcellbio

Improving therapeutic performance for predictive clinical outcomes through in vitro microenvironment control.

Founded 2012 United States San Francisco, United States 29 employees Corporate Round Total: $39.60M Biotechnology, Health Care +2

General Information

Company Name xcellbio
Founded Year 2012
Location United States San Francisco, United States
Employees 29
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Corporate Round
Social

BounceWatch is an independent company data service, not affiliated with xcellbio. To contact xcellbio, visit xcellbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does xcellbio compare?

A PDF of xcellbio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting xcellbio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About xcellbio

Xcell Biosciences (xcellbio) is a San Francisco-based life science company founded in 2012. The company aims to revolutionize the immunotherapy market by providing a primary cell control solution for research, drug discovery, and cell manufacturing. Its technology enables the maintenance, expansion, and control of various primary cell types, including immune cells, stem cells, and tumor cells. By offering bench-top primary cell control systems, reagent kits, software, and standardized protocols, Xcellbio seeks to democratize the manipulation of primary cells from blood or solid tissue. The company's technology, backed by LabCorp in the latest Corporate Round investment in April 2024, is designed to enhance immunotherapy efficacy, safety, and persistence. This patient-centric approach facilitates more predictive and iterative therapy development, as well as rapid, highly-controlled clinical cell manufacturing. Xcellbio's commitment to improving therapeutic performance for predictive clinical outcomes positions it as a key player in the Biotechnology and Manufacturing industries. For more information, please visit http://www.xcellbio.com/.

Business keywords: Life Science, Cell Therapy, Primary Cell Culture, Immunotherapy, Stem Cells, Cancer Research, Predictive Clinical Outcomes, Immunooncology, In Vitro Microenvironment Control, Cell Manufacturing, Immune Cells, Therapeutic Performance, Startup, San Francisco, Disruptive Technology

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Corporate Round Undisclosed 1
LabCorp
LabCorp
01 Apr 2024
Series B $27.50M 5
Casdin Capital Dynamk Capital Formic Ventures
Casdin Capital, Dynamk Capital +3
19 Jan 2022
Series A $12.00M 1
Viking Global Investors
Viking Global Investors
16 Feb 2017
Venture Round Undisclosed 1
Nimble Ventures
Nimble Ventures
06 May 2015
Convertible Note $100.00K 1
Illumina Accelerator
01 Oct 2014

xcellbio Alternatives & Competitors

View All Alternatives
xcellbio vs
Shinobi Therapeutics
Shinobi Therapeutics United States

Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond...

Series A
40 employees
Biotechnology, Health and Wellness
xcellbio vs
Inceptor Bio
Inceptor Bio United States

Advancing Cell and Gene Therapies to Cure Cancer

Debt Financing
28 employees
Biotechnology, Health Care
xcellbio vs
Abintus Bio, Inc.
Abintus Bio, Inc. United States

Empowering patients from within

Venture round
11 employees
Biotechnology, Health Care
Also compare with: xcellbio vs Celularity Inc. Celularity Inc. View all alternatives

FAQ About xcellbio

Improving therapeutic performance for predictive clinical outcomes through in vitro microenvironment control.
xcellbio was founded in 2012.
xcellbio is headquartered in San Francisco, United States.
xcellbio operates in Biotechnology, Health Care, Health and Wellness and Manufacturing. Its work centres on Life Science, Cell Therapy, Primary Cell Culture and Immunotherapy.
xcellbio has approximately 29 employees.
xcellbio has completed 5 funding rounds, raising a total of $39.60M. The latest funding stage is Corporate Round.
Top alternatives and competitors to xcellbio include Shinobi Therapeutics, Inceptor Bio, Abintus Bio, Inc., Alligator Bioscience, Celularity Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
xcellbio and Shinobi Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for xcellbio, https://bouncewatch.com/company/xcellbio, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout